Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MGNX Macrogenics Inc
- Stocks
- Healthcare
- NASDAQ: MGNX
Price (delayed)
$1.58
Market cap
$99.68M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.89
Enterprise value
-$8.42M
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its
Highlights
The revenue has increased by 2.7% QoQ
MGNX's net income has shrunk by 140% YoY but it is up by 17% QoQ
The EPS has plunged by 134% YoY but it has grown by 17% from the previous quarter
Macrogenics's equity has decreased by 32% QoQ and by 25% YoY
The quick ratio fell by 20% QoQ and by 13% YoY
Key stats
What are the main financial stats of MGNX
Market
Valuations
Earnings
Shares outstanding
63.09M
Market cap
$99.68M
Enterprise value
-$8.42M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.26
Price to sales (P/S)
0.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.05
Revenue
$154.05M
Gross profit
$138.47M
Operating income
-$99.45M
Net income
-$55.81M
EBIT
-$54.8M
EBITDA
-$48.21M
Free cash flow
-$72.24M
Per share
Balance sheet
Liquidity
EPS
-$0.89
EPS diluted
-$0.89
Free cash flow per share
-$1.15
Book value per share
$1.25
Revenue per share
$2.45
TBVPS
$3.57
Total assets
$224.57M
Total liabilities
$145.45M
Debt
$37.47M
Equity
$79.12M
Working capital
$126.65M
Debt to equity
0.47
Current ratio
3.28
Quick ratio
2.97
Net debt/EBITDA
2.24
Margins
Efficiency
Dividend
EBITDA margin
-31.3%
Gross margin
89.9%
Net margin
-36.2%
Operating margin
-64.6%
Return on assets
-23.5%
Return on equity
-59.8%
Return on invested capital
-79.8%
Return on capital employed
-32.4%
Return on sales
-35.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MGNX stock price
How has the Macrogenics stock price performed over time
Intraday
2.6%
1 week
10.49%
1 month
33.9%
1 year
-69.14%
YTD
-51.38%
QTD
24.41%
Financial performance
How have Macrogenics's revenue and profit performed over time
Revenue
$154.05M
Gross profit
$138.47M
Operating income
-$99.45M
Net income
-$55.81M
Gross margin
89.9%
Net margin
-36.2%
MGNX's net income has shrunk by 140% YoY but it is up by 17% QoQ
Macrogenics's operating margin has surged by 85% YoY and by 12% QoQ
The company's operating income rose by 46% YoY and by 10% QoQ
MGNX's net margin is up by 32% year-on-year and by 19% since the previous quarter
Price vs fundamentals
How does MGNX's price correlate with its fundamentals
Growth
What is Macrogenics's growth rate over time
Valuation
What is Macrogenics stock price valuation
P/E
N/A
P/B
1.26
P/S
0.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.05
The EPS has plunged by 134% YoY but it has grown by 17% from the previous quarter
The P/B is 65% below the 5-year quarterly average of 3.6 and 45% below the last 4 quarters average of 2.3
Macrogenics's equity has decreased by 32% QoQ and by 25% YoY
The price to sales (P/S) is 92% lower than the 5-year quarterly average of 8.2 and 74% lower than the last 4 quarters average of 2.5
The revenue has increased by 2.7% QoQ
Efficiency
How efficient is Macrogenics business performance
The ROS has grown by 28% YoY and by 18% from the previous quarter
MGNX's ROA is up by 15% from the previous quarter
MGNX's ROIC is down by 11% QoQ
MGNX's return on equity is up by 11% since the previous quarter
Dividends
What is MGNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MGNX.
Financial health
How did Macrogenics financials performed over time
The total assets is 54% more than the total liabilities
The quick ratio fell by 20% QoQ and by 13% YoY
MGNX's current ratio is down by 16% since the previous quarter and by 10% year-on-year
MGNX's debt is 53% smaller than its equity
The debt to equity is up by 47% since the previous quarter and by 47% year-on-year
Macrogenics's equity has decreased by 32% QoQ and by 25% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.